Journal Watch · Journal of Medicinal Chemistry · 2026

Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties.

Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.

Tarhan AK, Feng Z, Fernandez D et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c03612PMID: 42911737Study type: in-vitro / cell study

TL;DR

Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.

Key findings

  • These investigations have yielded the aryl-alkyl ether derivative IGUANA-5, a potent ALDH1B1 inhibitor that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits enhanced in vitro and in vivo pharmacological properties.
  • Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.

What they did

We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these limitations, we have explored bioisosteres of the biaryl moiety and modifications of the guanidine core.

Full abstract (original)

Background: ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-selective guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of three scaffold components: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues.

What they did: We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these limitations, we have explored bioisosteres of the biaryl moiety and modifications of the guanidine core.

Results & conclusions: These investigations have yielded the aryl-alkyl ether derivative IGUANA-5, a potent ALDH1B1 inhibitor that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits enhanced in vitro and in vivo pharmacological properties. Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c03612 · PubMed 42911737.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.

What type of study is this?

It is a in-vitro / cell study, published in Journal of Medicinal Chemistry in 2026. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c03612. PubMed ID: 42911737. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Tarhan AK, Feng Z, Fernandez D et al.. Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c03612.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/development-of-next-generation-aldh1b1-inhibitors-with-enhanced-pharmaco-c03612/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides